For the quarter ended June 2025, Astrazeneca (AZN) reported revenue of $14.46 billion, up 11.7% over the same period last year. EPS came in at $1.09, compared to $0.99 in the year-ago quarter.
The reported revenue represents a surprise of +3.04% over the Zacks Consensus Estimate of $14.03 billion. With the consensus EPS estimate being $1.09, the company has not delivered EPS surprise.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Astrazeneca performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- BioPharmaceuticals- CVRM- Farxiga- Established RoW: $106 million compared to the $106.86 million average estimate based on three analysts. The reported number represents a change of +2.9% year over year.
- BioPharmaceuticals- V&I- Europe: $24 million versus the three-analyst average estimate of $15.81 million. The reported number represents a year-over-year change of +242.9%.
- BioPharmaceuticals- CVRM- Lokelma- Established RoW: $37 million versus the three-analyst average estimate of $34.81 million. The reported number represents a year-over-year change of +32.1%.
- BioPharmaceuticals- CVRM- Crestor- Established RoW: $32 million compared to the $35.95 million average estimate based on three analysts. The reported number represents a change of -11.1% year over year.
- Oncology- Tagrisso- Established RoW: $209 million compared to the $215.72 million average estimate based on three analysts. The reported number represents a change of +9.4% year over year.
- Oncology- Imfinzi- Established RoW: $174 million versus $191.28 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -4.9% change.
- Oncology- Lynparza- Established RoW: $69 million compared to the $74.14 million average estimate based on three analysts. The reported number represents a change of +4.6% year over year.
- Oncology- Calquence- Established RoW: $42 million versus $36.78 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +27.3% change.
- Oncology- Established RoW: $591 million versus the three-analyst average estimate of $607.27 million. The reported number represents a year-over-year change of +5.4%.
- BioPharmaceuticals- R&I- Symbicort- Established RoW: $91 million versus $86.31 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.6% change.
- BioPharmaceuticals- R&I- Fasenra- Established RoW: $44 million compared to the $42.25 million average estimate based on three analysts. The reported number represents a change of +18.9% year over year.
- BioPharmaceuticals- R&I- Breztri- Established RoW: $25 million versus the three-analyst average estimate of $24.8 million. The reported number represents a year-over-year change of +31.6%.
View all Key Company Metrics for Astrazeneca here>>>
Shares of Astrazeneca have returned +2.8% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
